Corrigendum to “Effects of multikinase inhibitors on pressure overload-induced right ventricular remodeling” [International Journal of Cardiology 167 (2013) 2630–2637] (International Journal of Cardiology (2013) 167(6) (2630–2637), (S0167527312009369), (10.1016/j.ijcard.2012.06.129));Effects of multikinase inhibitors on pressure overload-induced right ventricular remodeling

International Journal of Cardiology

Volumn 167, Issue 6, 2013, Pages 2630-2637

  Kojonazarov, Baktybek ^a   Sydykov, Akylbek ^a   Pullamsetti, Soni Savai ^a,b   Luitel, Himal ^a   Dahal, Bhola K ^a   Kosanovic, Djuro ^a   Tian, Xia ^a   Majewski, Matthaeus ^a   Baumann, Christin ^a   Evans, Steve ^c   Phillips, Peter ^c   Fairman, David ^c   Davie, Neil ^c   Wayman, Chris ^c   Kilty, Iain ^c   Weissmann, Norbert ^a   Grimminger, Friedrich ^a   Seeger, Werner ^a,b   Ghofrani, Hossein Ardeschir ^a   Schermuly, Ralph Theo ^a  

^a JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^b MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

^c PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Pulmonary hypertension; Right ventricular remodeling; Sorafenib; Sunitinib

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; COLLAGEN TYPE 3; COLLAGEN TYPE 3 ALPHA 1; HLA B ANTIGEN; MONOCROTALINE; PLACEBO; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; ECHOCARDIOGRAPHY; HEART HEMODYNAMICS; HEART MUSCLE FIBROSIS; HEART RIGHT VENTRICLE FUNCTION; HEART RIGHT VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; MORPHOMETRICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RAT; TREATMENT OUTCOME;

PULMONARY HYPERTENSION; RIGHT VENTRICULAR REMODELING; SORAFENIB; SUNITINIB;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERTENSION, PULMONARY; INDOLES; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PYRROLES; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; VENTRICULAR FUNCTION, RIGHT; VENTRICULAR REMODELING;

EID: 84883780549     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2022.03.038     Document Type: Erratum

References (52)

1. N. Galie, M.M. Hoeper, and M. Humbert Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT) Eur Heart J 30 20 2009 2493 2537
2. N.W. Morrell, S. Adnot, and S.L. Archer Cellular and molecular basis of pulmonary arterial hypertension J Am Coll Cardiol 54 Suppl. 1 2009 S20 S31
3. S.A. van Wolferen, J.T. Marcus, and A. Boonstra Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension Eur Heart J 28 10 2007 1250 1257
4. H.C. Champion, E.D. Michelakis, and P.M. Hassoun Comprehensive invasive and noninvasive approach to the right ventricle-pulmonary circulation unit: state of the art and clinical and research implications Circulation 120 11 2009 992 1007
5. F. Haddad, S.A. Hunt, D.N. Rosenthal, and D.J. Murphy Right ventricular function in cardiovascular disease, part I: anatomy, physiology, aging, and functional assessment of the right ventricle Circulation 117 11 2008 1436 1448
6. S. Huez, J.L. Vachiery, P. Unger, S. Brimioulle, and R. Naeije Tissue Doppler imaging evaluation of cardiac adaptation to severe pulmonary hypertension Am J Cardiol 100 9 2007 1473 1478
7. A. Macchia, R. Marchioli, and R. Marfisi A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology Am Heart J 153 6 2007 1037 1047
8. R. Naeije, and S. Huez Expert opinion on available options treating pulmonary arterial hypertension Expert Opin Pharmacother 8 14 2007 2247 2265
9. A. Macchia, R. Marchioli, and G. Tognoni Systematic review of trials using vasodilators in pulmonary arterial hypertension: why a new approach is needed Am Heart J 159 2 2010 245 257
10. B.D. Fox, A. Shimony, and D. Langleben Meta-analysis of monotherapy versus combination therapy for pulmonary arterial hypertension Am J Cardiol 108 8 2011 1177 1182
11. M. Gomberg-Maitland, C. Dufton, R.J. Oudiz, and R.L. Benza Compelling evidence of long-term outcomes in pulmonary arterial hypertension? A clinical perspective J Am Coll Cardiol 57 9 2011 1053 1061
12. M. Humbert, G. Monti, and M. Fartoukh Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients Eur Respir J 11 3 1998 554 559
13. R.T. Schermuly, E. Dony, and H.A. Ghofrani Reversal of experimental pulmonary hypertension by PDGF inhibition J Clin Invest 115 10 2005 2811 2821
14. S. Wedgwood, J.M. Devol, and A. Grobe Fibroblast growth factor-2 expression is altered in lambs with increased pulmonary blood flow and pulmonary hypertension Pediatr Res 61 1 2007 32 36
15. M. Izikki, C. Guignabert, and E. Fadel Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents J Clin Invest 119 3 2009 512 523
16. H. Christou, A. Yoshida, V. Arthur, T. Morita, and S. Kourembanas Increased vascular endothelial growth factor production in the lungs of rats with hypoxia-induced pulmonary hypertension Am J Respir Cell Mol Biol 18 6 1998 768 776
17. S. Sakao, L. Taraseviciene-Stewart, and C.D. Cool VEGF-R blockade causes endothelial cell apoptosis, expansion of surviving CD34 + precursor cells and transdifferentiation to smooth muscle-like and neuronal-like cells FASEB J 21 13 2007 3640 3652
18. S.L. Merklinger, P.L. Jones, E.C. Martinez, and M. Rabinovitch Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension Circulation 112 3 2005 423 431
19. B.K. Dahal, T. Cornitescu, and A. Tretyn Role of epidermal growth factor inhibition in experimental pulmonary hypertension Am J Respir Crit Care Med 181 2 2010 158 167
20. C. Guignabert, C.M. Alvira, and T.P. Alastalo Tie2-mediated loss of peroxisome proliferator-activated receptor-gamma in mice causes PDGF receptor-beta-dependent pulmonary arterial muscularization Am J Physiol Lung Cell Mol Physiol 297 6 2009 L1082 L1090
21. H.A. Ghofrani, N.W. Morrell, and M.M. Hoeper Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy Am J Respir Crit Care Med 182 9 2010 1171 1177
22. M. Klein, R.T. Schermuly, and P. Ellinghaus Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling Circulation 118 20 2008 2081 2090
23. L. Moreno-Vinasco, M. Gomberg-Maitland, and M.L. Maitland Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension Physiol Genomics 33 2 2008 278 291
24. M. Gomberg-Maitland, M.L. Maitland, and R.J. Barst A dosing/cross- development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension Clin Pharmacol Ther 87 3 2010 303 310
25. R.J. Motzer, T.E. Hutson, and P. Tomczak Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2 2007 115 124
26. G.D. Demetri, A.T. van Oosterom, and C.R. Garrett Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial Lancet 368 9544 2006 1329 1338
27. D.S. Krause, and R.A. Van Etten Tyrosine kinases as targets for cancer therapy N Engl J Med 353 2 2005 172 187
28. T.J. Abrams, L.B. Lee, L.J. Murray, N.K. Pryer, and J.M. Cherrington SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer Mol Cancer Ther 2 5 2003 471 478
29. D.B. Mendel, A.D. Laird, and X. Xin In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship Clin Cancer Res 9 1 2003 327 337
30. C. Tei, L.H. Ling, and D.O. Hodge New index of combined systolic and diastolic myocardial performance: a simple and reproducible measure of cardiac function - a study in normals and dilated cardiomyopathy J Cardiol 26 6 1995 357 366
31. H.A. Ghofrani, W. Seeger, and F. Grimminger Imatinib for the treatment of pulmonary arterial hypertension N Engl J Med 353 13 2005 1412 1413
32. G.R. Zimmermann, J. Lehar, and C.T. Keith Multi-target therapeutics: when the whole is greater than the sum of the parts Drug Discov Today 12 1-2 2007 34 42
33. L. Piao, Y.H. Fang, and V.J. Cadete The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: resuscitating the hibernating right ventricle J Mol Med 88 1 2010 47 60
34. M.J. Faber, M. Dalinghaus, and I.M. Lankhuizen Right and left ventricular function after chronic pulmonary artery banding in rats assessed with biventricular pressure-volume loops Am J Physiol Heart Circ Physiol 291 4 2006 H1580 H1586
35. H.J. Bogaard, R. Natarajan, and S.C. Henderson Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure Circulation 120 20 2009 1951 1960
36. P.A. Davlouros, K. Niwa, G. Webb, and M.A. Gatzoulis The right ventricle in congenital heart disease Heart 92 Suppl. 1 2006 i27 i38
37. S. Schafer, P. Ellinghaus, and W. Janssen Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload-induced right-ventricular remodelling Cardiovasc Res 82 1 2009 30 39
38. M.H. Hessel, P. Steendijk, B. den Adel, C.I. Schutte, and A. van der Laarse Characterization of right ventricular function after monocrotaline- induced pulmonary hypertension in the intact rat Am J Physiol Heart Circ Physiol 291 5 2006 H2424 H2430
39. M.E. Campian, M. Hardziyenka, and K. de Bruin Early inflammatory response during the development of right ventricular heart failure in a rat model Eur J Heart Fail 12 7 2010 653 658
40. M.L. Handoko, F.S. de Man, and C.M. Happe Opposite effects of training in rats with stable and progressive pulmonary hypertension Circulation 120 1 2009 42 49
41. Y. Dor, V. Djonov, and R. Abramovitch Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy EMBO J 21 8 2002 1939 1947
42. Y. Izumiya, I. Shiojima, K. Sato, D.B. Sawyer, W.S. Colucci, and K. Walsh Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload Hypertension 47 5 2006 887 893
43. S.P. Levick, J.L. McLarty, D.B. Murray, R.M. Freeman, W.E. Carver, and G.L. Brower Cardiac mast cells mediate left ventricular fibrosis in the hypertensive rat heart Hypertension 53 6 2009 1041 1047
44. C.H. Liao, H. Akazawa, and M. Tamagawa Cardiac mast cells cause atrial fibrillation through PDGF-A-mediated fibrosis in pressure-overloaded mouse hearts J Clin Invest 120 1 2009 242 253
45. P. Dubreuil, S. Letard, and M. Ciufolini Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT PLoS One 4 9 2009 e7258
46. R. Tuuminen, A.I. Nykanen, and R. Krebs PDGF-A, -C, and -D but not PDGF-B increase TGF-beta1 and chronic rejection in rat cardiac allografts Arterioscler Thromb Vasc Biol 29 5 2009 691 698
47. O. Hudlicka, M. Brown, and S. Egginton Angiogenesis in skeletal and cardiac muscle Physiol Rev 72 2 1992 369 417
48. K.M. Chin, N.H. Kim, and L.J. Rubin The right ventricle in pulmonary hypertension Coron Artery Dis 16 1 2005 13 18
49. S. Wu, J.J. Chen, A. Kudelka, J. Lu, and X. Zhu Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis Lancet Oncol 9 2 2008 117 123
50. T.F. Chu, M.A. Rupnick, and R. Kerkela Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib Lancet 370 9604 2007 2011 2019
51. S. George, J.Y. Blay, and P.G. Casali Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure Eur J Cancer 45 11 2009 1959 1968
52. R.J. Motzer, M.D. Michaelson, and B.G. Redman Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma J Clin Oncol 24 1 2006 16 24